Skip to main content
OpenTrials
Completed

NCT Number: NCT02825173

Seal-G Safety Study

The purpose of this study is to farther assess the safety of the Seal-G Surgical Sealant for the reinforcement and protection of gastrointestinal anastomosis.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Rabin Medical Center, Petah Tikva, Israel

Loading trial locations.

About this study

Pre-Surgery:

Screening will be performed among adult subjects who are scheduled for an elective colorectal surgery. Pre-surgery assessments (after completion of consent process and signed ICF) will be according to the routine practice.

Intra-operative:

During surgery, an assessment of the intra-operative exclusion criteria will be performed. If the subject does not meet any of the exclusion criteria, the subject will be further enrolled. Surgery will be performed according to the site standard of care (routine practice). Anastomosis will be created either using a stapler device (linear or circular), according to manufacture IFU (Instructions for use) or hand suture according to surgeon best practice technique. Once anastomosis has been created, surgeon will verify the anastomosis and mucosal donuts integrity.

Device (Seal-G) application on anastomotic site

Post-operative follow-up: Follow-up evaluations will be performed daily while hospitalized. There will be one postoperative follow up at one month - clinic visit

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is ≥ 18 years old.
  • Subject is planned to undergo an elective open or laparoscopic colonic resection with the creation of an anastomosis (extracorporeal if laparoscopic surgery is performed).
  • Subject signs and dates a written ICF, indicates an understanding of the study procedures and follow-up requirements and is willing to comply with them.

Exclusion criteria

  • Subject, undergoing low anterior resection
  • Subject is planned to undergo an emergency procedure
  • Subject has a diagnosis of bowel strangulation, peritonitis, bowel perforation, local or systemic infection, ischemic bowel, and carcinomatosis
  • Subject treated with immunosuppressive agents within 28 days prior to study enrollment (including corticosteroids)
  • Serious or uncontrolled co-existent diseases (e.g. severe cardiovascular disease, congestive heart failure, recent myocardial infarction, significant vascular disease, active or uncontrolled autoimmune disease, active or uncontrolled infection)
  • Subject who according to the investigator clinical judgement is at risk for anastomosis dehiscence
  • Subject has participated in another clinical study which may affect this study's outcomes within the last 30 days
  • Subject's ASA (American Society of Anesthesiology) score ≥ 4
  • Subject's BMI > 34 or <16
  • Subject known to have distant metastases, such as liver, lung, bone etc. metastases (not including local and regional lymph nodes)
  • Subject with a life expectancy of less than 1 year
  • Subject requires more than one anastomosis during the surgery
  • Woman who is known to be pregnant
  • Mentally handicapped, prisoners, or legally incompetent

Intraoperative Exclusion Criteria:

  • Subjects whom anastomosis is less than 10 cm from the anal verge
  • The full circumference of the anastomosis is not accessible for Seal-G application
  • Subject received intraoperative sealant, glue or any buttressing material for the study related anastomosis, other than the Seal-G
  • Subject has excessive intraoperative bleeding prior to the anastomosis formation as assessed by the investigator (estimated in excess of 500mL)
  • Subject has peritoneal carcinomatosis

Treatment and study plan

Seal-G

Device

Intervention:

Device: Seal-G Seal-G is applied adjunctively to cover standard closure techniques

Other names: Seal-G Surgical Sealant

Primary outcomes

  1. Rate of device related complications

    Time frame: Postoperative to end of follow up (30±7 days)

Secondary outcomes

  1. Overall rate of complications

    Time frame: Postoperative to end of follow up (30±7 days)

  2. Postoperative length of hospitalization stay

    Time frame: Postoperative till time for "ready to be discharged" (10±4 days)

  3. Duration of sealant application

    Time frame: Intraoperative: starting from initial spreading on the treatment site to completion of curing, will be recorded (in minutes)

  4. Ease of use of the device

    Time frame: Intraoperative: device application

    Ease of use of the device will be rated using a Likert scale from 1 to 5 with: 1 being Very easy, 2 Easy, 3 Neutral, 4 Difficult and 5 being Very difficult. At the day of surgery (after surgery completed) the surgeon will complete a questionnaire regarding the device use and ease of application.

Sponsors and collaborators

Lead sponsor

Sealantis Ltd.

Industry

Registry information

Official study title

A Prospective, Multi-center, Open Label, Non-randomized Study, of Seal-G Surgical Sealant for the Reinforcement of Gastrointestinal Anastomosis

Important dates

Study start
2016
Primary completion
2016
Study completion
2016
First posted
Jul 7, 2016
Registry last updated
Apr 27, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.